Study demonstrates improved survival in women with metastatic breast cancer

September 24, 2003

Copenhagen, Denmark - September 24, 2003 - Today at the European Cancer Conference (ECCO) annual meeting, results from a randomized, Phase III study were presented which demonstrated that women with metastatic breast cancer who were treated with Taxotere (docetaxel) Injection Concentrate had a statistically significant improvement in overall survival and time to disease progression compared to those who were treated with paclitaxel. Both these agents are in a class of drugs knows as taxanes that are used extensively to treat women with metastatic breast cancer.

The multi-center study included 449 women who were randomized to either TaxotereÒ 100mg/m2 (1 hour infusion) or paclitaxel 175 mg/m2 (3 hour infusion) every three weeks. Treatment was continued until progression of disease, unmanageable toxicity or intercurrent illness occurred, or until the patient decided to terminate treatment for any other reason. Eligibility criteria included: bi-dimensionally measurable metastatic breast cancer, having failed either one prior anthracycline-based regimen as first-line therapy for metastatic breast cancer or disease progression during or within 12 months of completing anthracycline-based adjuvant or neoadjuvant chemotherapy.

"While Taxotere is already the most widely used chemotherapy agent in the treatment of women with metastatic breast cancer, this trial offers more hope to women with breast cancer and has significance in treatment decisions," said Peter Ravdin, M.D., Ph.D., an Associate Professor of Oncology at the University of Texas Health Science Center at San Antonio and Principal Investigator of the study. "Taxanes have been proven to be a leading class of agents across a wide range of cancers. This trial is an important comparison of the taxanes that may influence future research and treatment strategies."

The primary endpoint of this study was the rate of overall response (tumor shrinkage). The secondary endpoints included time to disease progression (time without the cancer growing) and overall survival. In the "intent to treat" population, results are as follows:

Taxotere was associated with increased incidence of grade 3/4 toxicities, including neutropenia (decrease in white blood cells which help fight infection), fever, diarrhea and edema (fluid retention).

"The study builds upon our base of research and provides additional support that Taxotere is one of the most active chemotherapy agents in the treatment of metastatic breast cancer after the failure of prior chemotherapy," said Michael L. Meyers, Senior Director, Oncology, Medical Affairs, Aventis Pharmaceuticals.
-end-
About Taxotere
Taxotere, a drug in the taxoid class of chemotherapeutic agents, inhibits cancer cell division by essentially "freezing" the cell's internal skeleton, which is comprised of microtubules.

Microtubules assemble and disassemble during a cell cycle. TaxotereÒ promotes their assembly and blocks their disassembly, thereby preventing cancer cells from dividing and resulting in cancer cell death.

Taxotere is currently approved in the United States to treat patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy, and patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with cisplatin, who had not received prior chemotherapy. It also is approved for patients with locally advanced or metastatic NSCLC after failure of prior platinum-based chemotherapy.

The most common severe side effects associated with Taxotere include low blood cell count, fatigue, fluid retention and mouth sores. The most common non-severe side effects included hair loss, neurosensory, cutaneous, nail changes, nausea and diarrhea. These side effects are generally reversible and manageable. A premedication regimen with corticosteroids is recommended in order to prevent or reduce hypersensitivity and fluid retention. Taxotere is not appropriate therapy for patients with significant liver impairment or a low white blood cell count.

Patients 65 years of age or older may experience some side effects more frequently. For more information about Taxotere, visit http://www.taxotere.com or see full prescribing information including boxed WARNINGS. For more information about ongoing clinical trials, please call 1-800-RxTrial or visit http://www.aventisoncology.com.

About Aventis
Aventis is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines. In 2002, Aventis generated sales of € 17.6 billion (US $16.6 billion), invested € 3.1 billion (US $3 billion) in research and development and employed approximately 71,000 people in its core business. Aventis corporate headquarters are in Strasbourg, France. The company's prescription drugs business is conducted in the U.S. by Aventis Pharmaceuticals Inc., which is headquartered in Bridgewater, New Jersey. For more information about Aventis in the U.S., please visit: www.aventis-us.com.

Full prescribing information is available by visiting the Aventis Pharmaceuticals U.S. Web site at http://www.aventis-us.com. Also available at this U.S. Web site are copies of this release or any recent release.

Statements in this news release containing projections or estimates of revenues, income, earnings per share, capital expenditures, capital structure, or other financial items; plans and objectives relating to future operations, products, or services; future economic performance; or assumptions underlying or relating to any such statements, are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the timing and effects of regulatory actions, the results of clinical trials, the company's relative success developing and gaining market acceptance for new products, the outcome of significant litigation, and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Report on Form 20-F of Aventis on file with the Securities and Exchange Commission and in the current Annual Report -"Document de Référence"- on file with the "Commission des Opérations de Bourse" in France.

Cohn & Wolfe

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.